Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The researchers reported that in a mouse model of alopecia areata, tofacitinib treatment influenced disease progression by modulating CD8⁺ T cell infiltration through the linoleic acid metabolism and magnesium ion pathway, offering insights into potential treatment approaches.

This study found that tofacitinib may inhibit CD8+ T cell infiltration in alopecia areata by affecting the linoleic acid metabolism-Mg2+ pathway in a sodium sulfide-induced mouse model, highlighting new insights for clinical diagnosis and treatment strategies.

This study found that in a mouse model of alopecia areata, tofacitinib inhibited CD8+ T cell infiltration at hair follicles by modulating linoleic acid metabolism and magnesium pathways, offering insights into potential therapeutic strategies for the condition.

This study revealed that tofacitinib may inhibit CD8⁺ T cell infiltration in alopecia areata by modulating the linoleic acid metabolism-Mg²⁺ pathway, providing new insights for potential treatments and diagnosis.

This study demonstrated the high effectiveness and safety of tofacitinib, a pan-JAK inhibitor, in treating severe forms of alopecia areata, although it is not yet FDA-approved for this condition.

This literature review found that Janus kinase inhibitors may help achieve remission in patients with refractory primary neutrophilic cicatricial alopecias, though data is limited to small case series and reports.

This review highlights new treatment options for alopecia, including JAK inhibitors and Wnt pathway-targeting therapies, which may offer better efficacy and safety than traditional treatments like minoxidil and finasteride, but notes the need for more research on long-term effects and patient-specific responses.

In this reported case, a 13-year-old boy with alopecia areata experienced complete lesion resolution and varied hair regrowth across different laser treatment parameters after three months of combined oral prednisone, topical ointment, and CO2 fractional laser therapy.

This article reviews treatment options for Alopecia Areata, concluding that topical corticosteroids are effective for mild cases, while systemic therapies are advised for moderate to severe cases.

This study observed that intradermal injections of Betamethasone were more effective than topical Clobetazole for treating alopecia areata in children, while Tofacitinib showed higher efficacy in those with atopic dermatitis.

In this case report, a 9-year-old with alopecia areata experienced full hair regrowth after six months of oral tofacitinib, with no recurrence or significant side effects for a year post-treatment.

JAK inhibitors improve hair growth in alopecia areata, especially in patchy types.

This study offers a comprehensive overview of alopecia, detailing its various types, diagnostic approaches, and treatment options, including updated medical and procedural interventions such as Tofacitinib, PRP therapy, and microneedling, among others.

In this case report, an 11-year-old girl with alopecia totalis initially treated with minoxidil experienced hypertrichosis, which reversed upon stopping the medication; hair regrowth on the scalp was achieved with tofacitinib after minoxidil discontinuation.

This case report highlights a rare association between congenital triangular alopecia and vitiligo, noting that treatment with tofacitinib improved the patient's vitiligo but not the alopecia.

This survey study reported the pricing, formulation, and delivery options for compounded topical alopecia medications in the tri-state area, finding varied costs and noting the capability of most pharmacies to exceed commercially available minoxidil concentrations and offer delivery services.

This research letter discusses the use of Janus kinase inhibitors for treating lichen planopilaris, although specific results or conclusions from the study are not provided.

This review concluded that oral tofacitinib and adalimumab are promising treatments for cicatricial alopecia, showing effectiveness in improving signs and symptoms but requiring regular monitoring for adverse effects. The authors emphasize the need for further extensive studies to solidify these findings.

This paper reviews the autoimmune disorder alopecia areata, its progression, and its significant emotional and psychological impact, but reports no new clinical findings.

This study reports that JAK inhibitors were effective in inducing remission in ulcerative colitis patients and presented an acceptable safety profile with a range of manageable side effects.

In this case report, the authors describe a rare association of alopecia universalis with frequently relapsing nephrotic syndrome in a 3-year-old girl, suggesting a possible genetic and immune-related cause, and note that tofacitinib treatment was ineffective in her case.

This study evaluated 32 marker compounds from natural herbal extracts and found that four of them, honokiol, isoalantolactone, broussochalcone A, and 3-deoxysappanone B, can induce hair growth, suggesting a potential natural treatment for hair loss.

This paper describes Grahams Little Piccardi Lassueur Syndrome, a rare type of Lichen Planopilaris that causes different types of alopecia and distinctive skin papules, primarily affecting females aged 40 to 70, and notes the current challenges in treatment options, particularly once scarring occurs.

This review discusses the use of Raman spectroscopy to evaluate drug penetration in alopecia treatments and suggests it may be a promising tool for enhancing the effectiveness of laser-assisted drug delivery.

This study found that oral Janus kinase inhibitors were effective in treating alopecia areata, with a clinical response rate of 48.3%, though further research is needed to assess long-term effects.

This review suggests that oral Janus kinase inhibitors like tofacitinib, ruxolitinib, and baricitinib show promise for treating alopecia areata in adults, both in terms of efficacy and safety.

This study reports that combining baricitinib with low-dose cyclosporine and steroids resulted in effective and safe treatment for a case of alopecia totalis, maintaining hair regrowth without adverse effects.

This review suggests that novel treatment developments targeting the pathomechanics of alopecia areata, such as JAK inhibitors, show promise, although optimal treatment strategies are still under investigation.

In this study, the alcoholic extract DN106212 from Centipeda minima was shown to be more effective in promoting hair growth in C57BL/6 mice compared to dimethyl sulfoxide and tofacitinib, suggesting its potential as a natural hair growth agent.

This research highlights that while JAK inhibitors are effective for various inflammatory conditions, studies raise concerns about increased risks of venous and arterial thromboembolism, and cancer, particularly with tofacitinib and baricitinib, leading to European guidelines recommending caution in high-risk patients.